4:00-5:00 Problem Solving Breakout Discussions
Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.
Engineering Alternative Scaffolds vs Engineering Antibodies--Are the Scaffolds Really Superior?
Moderator: Fredrik Frejd, Ph.D., Vice President, Research, Affibody AB
• Natural evolution vs man-made engineering
• So much is known about antibodies, why bother with new protein classes?
• Are scaffolds like Centyrins and Adnectins really different from single domain antibodies?
• Why antibody loops, when there are constraint surface secondary structures in DARPins and Affibody molecules
Antibody Viscosity: Causes, Effects and Remediation
Moderator: Randal Ketchem, Ph.D., Scientific Director, Therapeutic Discovery, Amgen Inc.
• Surface properties that affect viscosity
• Extra-molecular properties that impact viscosity
• Effects of viscosity on therapeutic antibodies
• Remediation of viscosity by extra-molecular sources
• Remediation of viscosity by direct engineering
Alternative Scaffolds vs. Antibodies – Making the Decision
Moderator: Kaspar Binz, Ph.D., Vice President & Co-Founder, Molecular Partners AG
• Advantages of scaffolds over antibodies and vice versa
• Ideal clinical applications of scaffolds and antibodies
• Engineering antibody products vs. scaffold products
• Research speed with different platforms
Use of Antibodies in Nanotech
Moderator: Carston Wagner, Ph.D., Professor, Medicinal Chemistry & Pharmacognosy, University of Minnesota
• Whole antibodies vs fragments
• Method of conjugation
• Characterization
Improving Antibody PK
Moderator: Javier Chaparro-Riggers, Ph.D., Senior Principal Scientist, Protein Engineering, Rinat Pfizer
|